Articles tagged with Drug Therapy
Scientists have developed a new way to alter the DNA of bacterial cells using high-frequency radio waves, outperforming traditional industry techniques. The process shows high efficiency and gentleness, with 91% of E. coli cells taking on the DNA after just three minutes.
After 7 to 12 years of follow-up, bariatric surgery outperformed medical/lifestyle intervention in achieving superior glycemic control with reduced medication use and higher rates of diabetes remission. Individuals who underwent bariatric surgery had better long-term management of their type 2 diabetes.
Researchers decode underlying mechanisms of DCM, hippocampal neurotoxicity, and dysbiosis mediated AD progression using mass spectrometry imaging. The studies found metabolic changes in DCM rat hearts and regulation of CYPs in the hippocampus, providing new perspectives on treatment strategies.
The Almodóvar lab is studying the link between HIV and pulmonary hypertension, a condition that increases pressure in lung arteries. By examining the interactions between different cell types and using a humanized mouse model, researchers hope to propose novel therapies to prevent lung diseases in people with HIV.
A novel chemotherapy approach uses patient's own cells as Trojan horses to deliver targeted cancer-killing drugs to lung cancer cells. The method has shown promise in reducing tumor size and improving treatment efficacy with minimal collateral damage to healthy tissues.
A UCF-developed technology uses a plasmonic platform to detect the chirality of molecules with high precision, enabling more accurate drug development and therapies. The platform improves upon current methods with sensitivity nearly 13 orders of magnitude greater.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.
Scientists create 'μkiss' technique for precise delivery of materials to individual cells, offering new possibilities in single-cell science and next-generation therapeutic applications. The method provides full control over location, time, and scale of material application, enabling detailed studies of cellular processes.
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body temperatures. This discovery could be useful in treatment to reverse Alzheimer’s Disease impact by degrading amyloid plaques.
Scientists at CeMM Research Center have discovered a new method to mark proteins for destruction, potentially treating diseases like cancer. The technique uses 'intramolecular bivalent glues' to alter the protein's surface, triggering targeted protein degradation via ubiquitin ligases.
Researchers at Texas A&M University have developed a coating that bolsters the safety of fresh produce and provides enhanced protection against bacteria and fungi. The coating combines wax with nano-encapsulated cinnamon-bark essential oil in protein carriers to enhance antibacterial properties.
A new study published in LANCET eClinicalMedicine found that regular exercise can help individuals maintain weight loss after completing medical weight loss treatment. The study showed that exercising just two hours a week can lead to better quality of life, improved mental health, and reduced fatigue.
A new study suggests that individuals with low income are frequently misdiagnosed and lack access to effective treatment for eating disorders. Researchers offer guidelines for therapists to make accommodations for these patients, including providing government or local food resources and engaging with local food banks.
Researchers at Tohoku University have developed a novel monoclonal antibody targeting HER2-positive breast cancer cells, providing a new tool for treating this aggressive subtype. The antibody disrupts cell growth and proliferation while minimizing harm to surrounding healthy tissue.
Researchers developed protein-like polymers to disrupt the Keap1/Nrf2 protein-protein interaction, preventing cellular damage and oxidative stress. This approach holds promise for treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
In a phase 2 clinical trial, zilebesiran significantly reduced 24-hour mean ambulatory systolic blood pressure in adults with mild to moderate hypertension. The treatment was administered subcutaneously at varying doses and intervals, demonstrating its potential as an RNA interference therapeutic for managing hypertension.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified the protein TYRP1 as a promising target for CAR T-cell therapy. The study demonstrates potent antitumor responses against cutaneous and rare melanoma types, offering new hope for treating these challenging-to-treat cancers.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
Scientists at the University of California, Riverside, have identified 898 RNA-dependent proteins in the deadliest human malaria parasite, Plasmodium falciparum. These findings could lead to novel therapeutic targets against malaria and highlight the importance of RNAs in biological pathways in the parasite.
A retrospective study found that PRRT was effective in controlling hypoglycemia in 81% of patients with malignant insulinomas, enabling 58% to reduce medication use. The treatment resulted in improved symptom control and reduced potential drug side effects for over 80% of patients.
Researchers discovered that aggregates prevent silencing of stress response in brain cells, leading to cell death. A new treatment involves administering a drug to turn off the stress response and keeping SIFI turned on to clean up protein aggregates.
A new tumor spatial mapping tool will help clinicians assess the aggressiveness of cancer and personalize treatment. The tool maps the functional state of oncoproteins onto tumour images, allowing for more accurate diagnosis and informed treatment decisions.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
A randomized clinical trial of 1,015 participants found that apixaban did not significantly reduce recurrent stroke risk compared to aspirin in patients with cryptogenic stroke and atrial cardiopathy. The study suggests that alternative treatments may be more effective for preventing stroke recurrence in these patients.
Researchers at La Jolla Institute for Immunology have identified 137 unique T cell epitopes targeted by the immune system in patients with active TB. These findings may lead to the development of new diagnostics and therapies for the disease, which affects over 1.3 million people worldwide.
Researchers discovered a new role for Mfsd7c in exporting excessive choline from the brain. The study suggests that targeting this protein could lead to therapeutic interventions for Alzheimer's disease and other neurological disorders.
Researchers grew lab-tumours from patient tissue to accurately predict drug effectiveness, showing high accuracy in identifying effective treatments and rejecting ineffective ones. The study paves the way for revolutionising personalised medicine and clinician-patient care through improved treatment selection.
A phase II clinical trial found Muse cell-based product CL2020 to be highly tolerated and improved ALS symptoms, but may not halt disease progression. The treatment's efficacy depends on combining it with other drugs for future treatments.
In a new study, researchers have identified a specific epigenetic pathway involved in the development of therapy resistance in melanoma. The study found that targeting this pathway with a small molecule inhibitor called corin can successfully resensitize therapy-resistant cancers to targeted therapies.
Researchers identified a next-generation BTK degrader that can destroy cellular targets and shrink tumors in drug-resistant CLL patients. The compound, NX-2127, showed promising results in laboratory studies and a phase 1 clinical trial.
A new study found that combining brain stimulation with intense physical rehabilitation helped stroke survivors recover movement in their arms and hands and maintain these improvements for one year. The pairing of rehabilitation therapy with vagus nerve stimulation likely helps the brain strengthen new neural pathways.
Researchers found that SGLT2 inhibitors reduced kidney stone rates by 30% compared to GLP1 agonists and 25% compared to DPP4 inhibitors. The study included data from 716,406 adults with type 2 diabetes who took these medications.
Researchers identified senescence-related tumor microenvironment genes associated with poor prognosis, genetic alterations, and reduced responsiveness to immunotherapy in HNSC. The study highlights the importance of precision medicine approaches for personalized treatment.
A Rutgers University study found that long-acting antipsychotic injections reduced 30-day rehospitalization rates for patients with schizophrenia or schizoaffective disorder by 75% compared to oral medication. This shift can have significant financial and medical benefits for both patients and hospitals.
A new tool, developed with a machine learning-based approach, can predict diuretic response in patients with ADHF. The BAN-ADHF score may lead to personalized strategies for effectively managing congestion in hospitalized patients.
A pilot study proposes a promising global genomic assay for diagnosing molecular subtypes in pediatric B-ALL, leading to more accurate diagnosis and targeted treatment options. RNA sequencing analysis accurately identified subtypes in all known cases and determined genetic subtype in 79% of previously unknown cases.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
Researchers develop technology that alleviates retinal pathologies by targeting mitochondrial chaperone TRAP1, which is implicated in the breakdown of blood-retinal barrier and pathological neovascularization. This treatment approach holds great promise for revolutionizing the treatment landscape for ischemic retinopathy.
A new study published in Neurology found that young Black and Hispanic women with multiple sclerosis face greater challenges in pregnancy, have more advanced disease, and experience higher inflammation levels, which may signal MS progression. The researchers also noted disparities in healthcare access and treatment.
Stacyann Bailey studies how cancer treatment affects bones, hoping to prevent fractures and improve patient outcomes. Up to 50% of patients with metastatic bone disease develop fractures due to treatment, making her work crucial for their quality of life.
Researchers developed computational algorithms to analyze patient data and discovered a protein, NME2, that works closely with MYC in advanced prostate cancer cells resistant to enzalutamide. Reducing NME2 levels restored the drug's efficacy, offering new hope for patients who initially respond poorly.
Researchers have effectively targeted three distinct groups of cholangiocarcinoma, a lethal disease caused by liver fluke parasite or herbal carcinogen exposure. Experimental models show that specific treatments targeting these pathways can slow cancer growth and improve prognosis for CCA patients
Researchers found that 94% of patients with posterior cortical atrophy had Alzheimer's pathology, while only 70% of those with memory loss did. Early identification of PCA may lead to better treatment options for Alzheimer's patients.
A team of researchers from UMass Amherst and Seattle Children's Research Institute found that prior exposure to certain bacteria changes the lung's innate immune response, making it more vulnerable to tuberculosis. The study suggests that remodeling the innate immune system could be a more effective strategy in fighting TB.
Researchers at Nagoya University have discovered a relationship between ALS progression and the disruption of mitochondria-associated membranes (MAM) and TBK1 activity. Decreased activation of TBK1 is linked to motor neuron death in ALS patients and mice with disrupted MAM.
Researchers at Cleveland Clinic have developed a peptide therapeutic that blocks aggressive cancer cells from multiplying rapidly. The treatment disrupts the molecular processes behind cancer growth and induces tumor cell death, making it a promising new strategy for treating triple-negative breast cancer.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers at St. Jude Children's Research Hospital have developed a molecular glue that sticks to the cancer-related protein casein kinase 1 alpha (CK1α), leading to its destruction. The compound, SJ3149, displays broad anti-cancer activity and may have clinical utility as an alternative to conventional small molecule inhibitors.
A new task force launched by C-Path aims to accelerate drug development for mitochondrial and inherited metabolic diseases. The task force will leverage C-Path's expertise in data management standards, biomarkers, and regulatory science to generate solutions and contribute to regulatory decision-making.
A systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types. Researchers used machine learning methods to find promising targets and linked them to specific biological markers and genetic features.
Researchers have successfully used mRNA technology to correct a rare genetic disease in mice, demonstrating its potential therapeutic use. The treatment corrected the lethal consequences of the disease and restored glutathione metabolism.
Researchers found a shared genetic trait that predicts a higher risk of small lung vessel disease and its severe form, pulmonary arterial hypertension. This discovery could lead to personalized treatments for patients with limited oxygen response.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
Researchers from Zhejiang University School of Medicine have revealed key connections between clinical characteristics, neuroimaging, and treatment in obsessive-compulsive disorder (OCD). The study found that about 13-36% of patients show poor insight, linked to more severe symptoms and poorer treatment outcomes.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
A large-scale German-wide randomized controlled trial found that high-dose therapy with glucocorticoids is not more effective than standard treatment for sudden hearing loss. However, it was associated with a higher risk of side effects. Several hundred thousand people worldwide suffer from sudden hearing loss each year.
Researchers have developed a new method to generate cyclic peptides that can target diseases and be administered orally, overcoming challenges in protein binding. The approach enables high-throughput screening and has shown substantial bioavailability in rats, opening possibilities for treating various diseases.
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
The number of new dermatologic drug approvals by the FDA increased significantly between 2012 and 2022, with nearly half considered first in class or indication. This surge in approvals was deemed clinically useful or to have high added therapeutic benefit by health technology assessment organizations.